1. A thermoelectric transducing material comprising a layered cobaltite based substance represented by the chemical formula AxCoO2, wherein x is not less than 0.2 and not more than 1 and wherein A consists of an element selected from the group consisting of Na, K, Sr, Ca and Ba, and is compositionally modulated in a thickness-wise direction of layers in a structure of the layered cobaltite based substance.
2. The thermoelectric transducing material according to claim 1, wherein x is not less than 0.3 and not more than 0.7.
3. The thermoelectric transducing material according to claim 3, wherein x is not less than 0.4 and not more than 0.6.
4. The thermoelectric transducing material according to claim 1, wherein the layering of AxCoO2 layers corresponding to the respective kinds of elements or element groups is repeated in a layering direction.
5. The thermoelectric transducing material according to claim 1, wherein the thermoelectric transducing material comprises plural kinds of element A, and A is compositionally modulated by layering AxCoO2 layers corresponding to the respective kinds of elements or element groups.
6. The thermoelectric transducing material according to claim 1, wherein the thermoelectric transducing material comprises plural kinds of element A.
7. A thermoelectric transducing material comprising a plural layered cobaltite based substance, at least one layer represented by the chemical formula A\u2032xCoO2 and at least one other layer represented by the formula A\u2033xCoO2, wherein x is not less than 0.2 and not more than 1 and wherein A\u2032 and A\u2033 each consists of an element selected from the group consisting of Na, K, Sr, Ca and Ba, the layered cobaltite based substance is structured such that at least one A\u2032xCoO2 layer and at least one A\u2033xCoO2 layer are stacked in a layer thickness direction, and is compositionally modulated in a thickness-wise direction of layers in a structure of the layered cobaltite based substance and A\u2032 and A\u2033 are different elements.
8. The thermoelectric transducing material according to claim 7, wherein A\u2032 is an alkali metal element and A\u2033 is an alkaline earth element.
9. The thermoelectric transducing material according to claim 8, wherein a thermoelectric transduction power factor P is 1.5 mWK2m or more.
10. The thermoelectric transducing material according to claim 7, wherein A\u2032 is an element or element group consisting of an alkali metal element and a thickness of the A\u2032xCoO2 layer is not less than 1 nm and not more than 3 nm.
11. The thermoelectric transducing material according to claim 7, wherein A\u2033 is an element or element group consisting of an alkali earth group element and a thickness of the A\u2033xCoO2 layer is not less than 2 nm and not more than 8 nm.
12. The thermoelectric transducing material according to claim 7, wherein a thickness of the A\u2032xCoO2 layer is not less than 1 nm and not more than 3 nm, while a thickness of the A\u2033xCoO2 layer is not less than 2 nm and not more than 8 nm.
13. The thermoelectric transducing material according to claim 12, wherein the thermoelectric transduction power factor P is 2 mWK2m or more.
14. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Na and A\u2033 is Sr.
15. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Na and A\u2033 is K.
16. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Na and A\u2033 is Ca.
17. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Na and A\u2033 is Ba.
18. The thermoelectric transducing material according to claim 7, wherein A\u2032 is K and A\u2033 is Ca.
19. The thermoelectric transducing material according to claim 7, wherein A\u2032 is K and A\u2033 is Sr.
20. The thermoelectric transducing material according to claim 7, wherein A\u2032 is K and A\u2033 is Ba.
21. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Ca and A\u2033 is Sr.
22. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Ca and A\u2033 is Ba.
23. The thermoelectric transducing material according to claim 7, wherein A\u2032 is Sr and A\u2033 is Ba.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. Chemical compounds combinations suitable for treatment of vaginal herpes simplex disease comprising:
a physically inert carrier suppository composition which is solid at room temperature and fluid at human body temperature; and
a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of
31
wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl; or
32
wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 ism ethyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl, or
33
2. Chemical compound combination suitable for treatment of herpes simplex disease comprising:
a water soluble physiologically inert compatible base, and
a 0.01 to 5.0 wt % concentration of an amino acid selected from the class of consisting of
34
wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl; or
35
wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl; or
36
3. A process for treating herpes simplex disease infection of humans comprising:
applying a composition of a water soluble physiologically inert compatible base; and
a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of
37
wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydroge n, methyl, acetyl, or carbamyl; or
38
wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to fur carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl; or
39
wherein none, one, two or three of R13, R14, R15 and R16 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and none or one of R13, R14, R15 and R16 is imino, all others of said R13, R14, R15 and R16 being hydrogen, and R18 is hydrogen, methyl, acetyl or carbamyl; or
40
wherein none, one or two of R20, R21 and R22 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, all others of R20, R21 and R22 being hydrogen, R23 is hydrogen, methyl, acetyl, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether or isopropenyl, and R24 is hydrogen, methyl, acetyl or carbamyl; or
41
wherein none, one, two or three of R30, R32 and R33 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or amino, all others of R31, R32, R33 being hydrogen, R34 is hydrogen, methyl, acetyl, amino, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or isopropenyl, and R35 is hydrogen, methyl, acetyl or carbamyl; or
42
wherein none, one, two or three of R40, R41 and R42 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R40, R41 and R42 are hydrogen, R43 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, or acetimidoyl, and R44 is hydrogen, methyl, acetyl, or carbamyl.